{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,15]],"date-time":"2026-11-15T01:07:47Z","timestamp":1794704867008,"version":"4.9.1"},"reference-count":87,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,3,2]],"date-time":"2023-03-02T00:00:00Z","timestamp":1677715200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,3,2]],"date-time":"2023-03-02T00:00:00Z","timestamp":1677715200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Transl Med"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Mammalian cells responding to specific perturbations of homeostasis can undergo a regulated variant of cell death that elicits adaptive immune responses. As immunogenic cell death (ICD) can only occur in a precise cellular and organismal context, it should be conceptually differentiated from instances of immunostimulation or inflammatory responses that do not mechanistically depend on cellular demise. Here, we critically discuss key conceptual and mechanistic aspects of ICD and its implications for cancer (immuno)therapy.<\/jats:p>","DOI":"10.1186\/s12967-023-04017-6","type":"journal-article","created":{"date-parts":[[2023,3,2]],"date-time":"2023-03-02T05:02:53Z","timestamp":1677733373000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":191,"title":["Immunogenic cell death in cancer: concept and therapeutic implications"],"prefix":"10.1186","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2257-8500","authenticated-orcid":false,"given":"Lorenzo","family":"Galluzzi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oliver","family":"Kepp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erik","family":"Hett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guido","family":"Kroemer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco M.","family":"Marincola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,3,2]]},"reference":[{"key":"4017_CR1","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1038\/s41580-020-0250-z","volume":"21","author":"C Hetz","year":"2020","unstructured":"Hetz C, Zhang K, Kaufman RJ. Mechanisms, regulation and functions of the unfolded protein response. Nat Rev Mol Cell Biol. 2020;21:421\u201338.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"4017_CR2","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1038\/s41580-018-0068-0","volume":"19","author":"L Galluzzi","year":"2018","unstructured":"Galluzzi L, Yamazaki T, Kroemer G. Linking cellular stress responses to systemic homeostasis. Nat Rev Mol Cell Biol. 2018;19:731\u201345.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"4017_CR3","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1146\/annurev-genet-102808-114910","volume":"43","author":"C He","year":"2009","unstructured":"He C, Klionsky DJ. Regulation mechanisms and signaling pathways of autophagy. Annu Rev Genet. 2009;43:67\u201393.","journal-title":"Annu Rev Genet"},{"key":"4017_CR4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/bs.ircmb.2021.03.003","volume":"363","author":"J Groenendyk","year":"2021","unstructured":"Groenendyk J, Agellon LB, Michalak M. Calcium signaling and endoplasmic reticulum stress. Int Rev Cell Mol Biol. 2021;363:1\u201320.","journal-title":"Int Rev Cell Mol Biol"},{"key":"4017_CR5","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/bs.ircmb.2022.08.003","volume":"373","author":"SJ Hofer","year":"2022","unstructured":"Hofer SJ, Kroemer G, Kepp O. Autophagy-inducing nutritional interventions in experimental and clinical oncology. Int Rev Cell Mol Biol. 2022;373:125\u201358.","journal-title":"Int Rev Cell Mol Biol"},{"key":"4017_CR6","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/bs.ircmb.2019.12.004","volume":"352","author":"DR Miller","year":"2020","unstructured":"Miller DR, Cramer SD, Thorburn A. The interplay of autophagy and non-apoptotic cell death pathways. Int Rev Cell Mol Biol. 2020;352:159\u201387.","journal-title":"Int Rev Cell Mol Biol"},{"key":"4017_CR7","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/bs.ircmb.2020.01.003","volume":"352","author":"WD Fairlie","year":"2020","unstructured":"Fairlie WD, Tran S, Lee EF. Crosstalk between apoptosis and autophagy signaling pathways. Int Rev Cell Mol Biol. 2020;352:115\u201358.","journal-title":"Int Rev Cell Mol Biol"},{"key":"4017_CR8","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1016\/j.tcb.2020.03.004","volume":"30","author":"SJF Chong","year":"2020","unstructured":"Chong SJF, Marchi S, Petroni G, Kroemer G, Galluzzi L, Pervaiz S. Noncanonical cell fate regulation by Bcl-2 proteins. Trends Cell Biol. 2020;30:537\u201355.","journal-title":"Trends Cell Biol"},{"key":"4017_CR9","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1038\/s41418-017-0012-4","volume":"25","author":"L Galluzzi","year":"2018","unstructured":"Galluzzi L, Vitale I, Aaronson SA, Abrams JM, Adam D, Agostinis P, Alnemri ES, Altucci L, Amelio I, Andrews DW, et al. Molecular mechanisms of cell death: recommendations of the nomenclature Committee on Cell Death 2018. Cell Death Differ. 2018;25:486\u2013541.","journal-title":"Cell Death Differ"},{"key":"4017_CR10","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1038\/s41590-022-01132-2","volume":"23","author":"G Kroemer","year":"2022","unstructured":"Kroemer G, Galassi C, Zitvogel L, Galluzzi L. Immunogenic cell stress and death. Nat Immunol. 2022;23:487\u2013500.","journal-title":"Nat Immunol"},{"key":"4017_CR11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/bs.ircmb.2019.11.006","volume":"350","author":"A Wu Chuang","year":"2020","unstructured":"Wu Chuang A, Kepp O, Kroemer G, Bezu L. Endoplasmic reticulum stress in the cellular release of damage-associated molecular patterns. Int Rev Cell Mol Biol. 2020;350:1\u201328.","journal-title":"Int Rev Cell Mol Biol"},{"key":"4017_CR12","doi-asserted-by":"publisher","first-page":"402","DOI":"10.3389\/fimmu.2015.00402","volume":"6","author":"J Fucikova","year":"2015","unstructured":"Fucikova J, Moserova I, Urbanova L, Bezu L, Kepp O, Cremer I, Salek C, Strnad P, Kroemer G, Galluzzi L, Spisek R. Prognostic and predictive value of DAMPs and DAMP-Associated processes in Cancer. Front Immunol. 2015;6:402.","journal-title":"Front Immunol"},{"key":"4017_CR13","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1038\/nrc3380","volume":"12","author":"DV Krysko","year":"2012","unstructured":"Krysko DV, Garg AD, Kaczmarek A, Krysko O, Agostinis P, Vandenabeele P. Immunogenic cell death and DAMPs in cancer therapy. Nat Rev Cancer. 2012;12:860\u201375.","journal-title":"Nat Rev Cancer"},{"key":"4017_CR14","doi-asserted-by":"publisher","first-page":"1094","DOI":"10.1016\/j.cell.2019.04.024","volume":"177","author":"DR Green","year":"2019","unstructured":"Green DR. The coming decade of cell death research: five riddles. Cell. 2019;177:1094\u2013107.","journal-title":"Cell"},{"key":"4017_CR15","doi-asserted-by":"crossref","unstructured":"Galluzzi L, Vitale I, Warren S, Adjemian S, Agostinis P, Martinez AB, Chan TA, Coukos G, Demaria S, Deutsch E et al. Consensus guidelines for the definition, detection and interpretation of immunogenic cell death. J Immunother Cancer2020,8.","DOI":"10.1136\/jitc-2019-000337corr1"},{"key":"4017_CR16","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1016\/j.trecan.2020.01.001","volume":"6","author":"I Melero","year":"2020","unstructured":"Melero I, Alvarez M, Minute L, Berraondo P. Premortem Tumor stress in Radioimmunotherapy. Trends Cancer. 2020;6:173\u20134.","journal-title":"Trends Cancer"},{"key":"4017_CR17","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1038\/s41419-020-03221-2","volume":"11","author":"J Fucikova","year":"2020","unstructured":"Fucikova J, Kepp O, Kasikova L, Petroni G, Yamazaki T, Liu P, Zhao L, Spisek R, Kroemer G, Galluzzi L. Detection of immunogenic cell death and its relevance for cancer therapy. Cell Death Dis. 2020;11:1013.","journal-title":"Cell Death Dis"},{"key":"4017_CR18","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1038\/s41571-020-0413-z","volume":"17","author":"L Galluzzi","year":"2020","unstructured":"Galluzzi L, Humeau J, Buqu\u00e9 A, Zitvogel L, Kroemer G. Immunostimulation with chemotherapy in the era of immune checkpoint inhibitors. Nat Rev Clin Oncol. 2020;17:725\u201341.","journal-title":"Nat Rev Clin Oncol"},{"key":"4017_CR19","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1016\/j.ccell.2020.11.009","volume":"39","author":"G Petroni","year":"2021","unstructured":"Petroni G, Buqu\u00e9 A, Zitvogel L, Kroemer G, Galluzzi L. Immunomodulation by targeted anticancer agents. Cancer Cell. 2021;39:310\u201345.","journal-title":"Cancer Cell"},{"key":"4017_CR20","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1038\/s41590-019-0561-4","volume":"21","author":"ME Rodriguez-Ruiz","year":"2020","unstructured":"Rodriguez-Ruiz ME, Vitale I, Harrington KJ, Melero I, Galluzzi L. Immunological impact of cell death signaling driven by radiation on the tumor microenvironment. Nat Immunol. 2020;21:120\u201334.","journal-title":"Nat Immunol"},{"key":"4017_CR21","doi-asserted-by":"crossref","unstructured":"Minute L, Teijeira A, Sanchez-Paulete AR, Ochoa MC, Alvarez M, Otano I, Etxeberrria I, Bola\u00f1os E, Azpilikueta A, Garasa S et al. Cellular cytotoxicity is a form of immunogenic cell death. J Immunother Cancer2020,8.","DOI":"10.1136\/jitc-2019-000325"},{"key":"4017_CR22","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.1084\/jem.20050915","volume":"202","author":"N Casares","year":"2005","unstructured":"Casares N, Pequignot MO, Tesniere A, Ghiringhelli F, Roux S, Chaput N, Schmitt E, Hamai A, Hervas-Stubbs S, Obeid M, et al. Caspase-dependent immunogenicity of doxorubicin-induced tumor cell death. J Exp Med. 2005;202:1691\u2013701.","journal-title":"J Exp Med"},{"key":"4017_CR23","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1038\/s41586-020-2079-1","volume":"579","author":"Q Wang","year":"2020","unstructured":"Wang Q, Wang Y, Ding J, Wang C, Zhou X, Gao W, Huang H, Shao F, Liu Z. A bioorthogonal system reveals antitumour immune function of pyroptosis. Nature. 2020;579:421\u20136.","journal-title":"Nature"},{"key":"4017_CR24","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/bs.ircmb.2019.07.005","volume":"348","author":"F Kotsias","year":"2019","unstructured":"Kotsias F, Cebrian I, Alloatti A. Antigen processing and presentation. Int Rev Cell Mol Biol. 2019;348:69\u2013121.","journal-title":"Int Rev Cell Mol Biol"},{"key":"4017_CR25","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/bs.ircmb.2019.07.008","volume":"348","author":"J Martinek","year":"2019","unstructured":"Martinek J, Wu TC, Cadena D, Banchereau J, Palucka K. Interplay between dendritic cells and cancer cells. Int Rev Cell Mol Biol. 2019;348:179\u2013215.","journal-title":"Int Rev Cell Mol Biol"},{"key":"4017_CR26","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1186\/s13045-020-00939-6","volume":"13","author":"Y Wang","year":"2020","unstructured":"Wang Y, Xiang Y, Xin VW, Wang XW, Peng XC, Liu XQ, Wang D, Li N, Cheng JT, Lyv YN, et al. Dendritic cell biology and its role in tumor immunotherapy. J Hematol Oncol. 2020;13:107.","journal-title":"J Hematol Oncol"},{"key":"4017_CR27","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1016\/j.immuni.2020.04.011","volume":"52","author":"MEW Logtenberg","year":"2020","unstructured":"Logtenberg MEW, Scheeren FA, Schumacher TN. The CD47-SIRP\u03b1 immune checkpoint. Immunity. 2020;52:742\u201352.","journal-title":"Immunity"},{"key":"4017_CR28","doi-asserted-by":"publisher","first-page":"2051","DOI":"10.1126\/science.288.5473.2051","volume":"288","author":"PA Oldenborg","year":"2000","unstructured":"Oldenborg PA, Zheleznyak A, Fang YF, Lagenaur CF, Gresham HD, Lindberg FP. Role of CD47 as a marker of self on red blood cells. Science. 2000;288:2051\u20134.","journal-title":"Science"},{"key":"4017_CR29","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1038\/s41422-020-0383-9","volume":"31","author":"J Fucikova","year":"2021","unstructured":"Fucikova J, Spisek R, Kroemer G, Galluzzi L. Calreticulin and cancer. Cell Res. 2021;31:5\u201316.","journal-title":"Cell Res"},{"key":"4017_CR30","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1111\/j.1749-6632.2010.05740.x","volume":"1209","author":"I Martins","year":"2010","unstructured":"Martins I, Kepp O, Galluzzi L, Senovilla L, Schlemmer F, Adjemian S, Menger L, Michaud M, Zitvogel L, Kroemer G. Surface-exposed calreticulin in the interaction between dying cells and phagocytes. Ann N Y Acad Sci. 2010;1209:77\u201382.","journal-title":"Ann N Y Acad Sci"},{"key":"4017_CR31","doi-asserted-by":"publisher","first-page":"127","DOI":"10.3389\/fimmu.2018.00127","volume":"9","author":"S Gordon","year":"2018","unstructured":"Gordon S, Pl\u00fcddemann A. Macrophage clearance of apoptotic cells: a critical assessment. Front Immunol. 2018;9:127.","journal-title":"Front Immunol"},{"key":"4017_CR32","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1038\/s41571-022-00619-z","volume":"19","author":"WH Fridman","year":"2022","unstructured":"Fridman WH, Meylan M, Petitprez F, Sun CM, Italiano A, Saut\u00e8s-Fridman C. B cells and tertiary lymphoid structures as determinants of tumour immune contexture and clinical outcome. Nat Rev Clin Oncol. 2022;19:441\u201357.","journal-title":"Nat Rev Clin Oncol"},{"key":"4017_CR33","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1016\/j.tcb.2019.01.003","volume":"29","author":"I Vitale","year":"2019","unstructured":"Vitale I, Sistigu A, Manic G, Rudqvist NP, Trajanoski Z, Galluzzi L. Mutational and antigenic landscape in tumor progression and cancer immunotherapy. Trends Cell Biol. 2019;29:396\u2013416.","journal-title":"Trends Cell Biol"},{"key":"4017_CR34","doi-asserted-by":"publisher","first-page":"xi","DOI":"10.1016\/S1937-6448(19)30009-7","volume":"342","author":"NP Rudqvist","year":"2019","unstructured":"Rudqvist NP, Galluzzi L. T cells: friends and foes. Int Rev Cell Mol Biol. 2019;342:xi\u2013xiv.","journal-title":"Int Rev Cell Mol Biol"},{"key":"4017_CR35","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1146\/annurev-pathmechdis-012419-032847","volume":"15","author":"J Zindel","year":"2020","unstructured":"Zindel J, Kubes P. DAMPs, PAMPs, and LAMPs in immunity and sterile inflammation. Annu Rev Pathol. 2020;15:493\u2013518.","journal-title":"Annu Rev Pathol"},{"key":"4017_CR36","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1038\/nature12213","volume":"499","author":"MS Lawrence","year":"2013","unstructured":"Lawrence MS, Stojanov P, Polak P, Kryukov GV, Cibulskis K, Sivachenko A, Carter SL, Stewart C, Mermel CH, Roberts SA, et al. Mutational heterogeneity in cancer and the search for new cancer-associated genes. Nature. 2013;499:214\u20138.","journal-title":"Nature"},{"key":"4017_CR37","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1038\/s41571-021-00508-x","volume":"18","author":"L Zitvogel","year":"2021","unstructured":"Zitvogel L, Perreault C, Finn OJ, Kroemer G. Beneficial autoimmunity improves cancer prognosis. Nat Rev Clin Oncol. 2021;18:591\u2013602.","journal-title":"Nat Rev Clin Oncol"},{"key":"4017_CR38","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1038\/s41571-020-0387-x","volume":"17","author":"SP Haen","year":"2020","unstructured":"Haen SP, L\u00f6ffler MW, Rammensee HG, Brossart P. Towards new horizons: characterization, classification and implications of the tumour antigenic repertoire. Nat Rev Clin Oncol. 2020;17:595\u2013610.","journal-title":"Nat Rev Clin Oncol"},{"key":"4017_CR39","doi-asserted-by":"publisher","first-page":"eabl3795","DOI":"10.1126\/sciimmunol.abl3795","volume":"7","author":"CC Clement","year":"2022","unstructured":"Clement CC, Osan J, Buque A, Nanaware PP, Chang YC, Perino G, Shetty M, Yamazaki T, Tsai WL, Urbanska AM, et al. PDIA3 epitope-driven immune autoreactivity contributes to hepatic damage in type 2 diabetes. Sci Immunol. 2022;7:eabl3795.","journal-title":"Sci Immunol"},{"key":"4017_CR40","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.1084\/jem.183.3.1173","volume":"183","author":"Y Guilloux","year":"1996","unstructured":"Guilloux Y, Lucas S, Brichard VG, Van Pel A, Viret C, De Plaen E, Brasseur F, Lethe B, Jotereau F, Boon T. A peptide recognized by human cytolytic T lymphocytes on HLA-A2 melanomas is encoded by an intron sequence of the N-acetylglucosaminyltransferase V gene. J Exp Med. 1996;183:1173\u201383.","journal-title":"J Exp Med"},{"key":"4017_CR41","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1038\/msb.2011.68","volume":"7","author":"E Caron","year":"2011","unstructured":"Caron E, Vincent K, Fortier MH, Laverdure JP, Bramoull\u00e9 A, Hardy MP, Voisin G, Roux PP, Lemieux S, Thibault P, Perreault C. The MHC I immunopeptidome conveys to the cell surface an integrative view of cellular regulation. Mol Syst Biol. 2011;7:533.","journal-title":"Mol Syst Biol"},{"key":"4017_CR42","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1038\/nrm3999","volume":"16","author":"Y Fuchs","year":"2015","unstructured":"Fuchs Y, Steller H. Live to die another way: modes of programmed cell death and the signals emanating from dying cells. Nat Rev Mol Cell Biol. 2015;16:329\u201344.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"4017_CR43","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1038\/s41423-022-00956-0","volume":"20","author":"J Chen","year":"2023","unstructured":"Chen J, Jin Z, Zhang S, Zhang X, Li P, Yang H, Ma Y. Arsenic trioxide elicits prophylactic and therapeutic immune responses against solid tumors by inducing necroptosis and ferroptosis. Cell Mol Immunol. 2023;20:51\u201364.","journal-title":"Cell Mol Immunol"},{"key":"4017_CR44","doi-asserted-by":"publisher","first-page":"2059878","DOI":"10.1080\/2162402X.2022.2059878","volume":"11","author":"J Le Naour","year":"2022","unstructured":"Le Naour J, Sztupinszki Z, Carbonnier V, Casiraghi O, Marty V, Galluzzi L, Szallasi Z, Kroemer G, Vacchelli E. A loss-of-function polymorphism in ATG16L1 compromises therapeutic outcome in head and neck carcinoma patients. Oncoimmunology. 2022;11:2059878.","journal-title":"Oncoimmunology"},{"key":"4017_CR45","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1038\/nri.2016.107","volume":"17","author":"L Galluzzi","year":"2017","unstructured":"Galluzzi L, Buqu\u00e9 A, Kepp O, Zitvogel L, Kroemer G. Immunogenic cell death in cancer and infectious disease. Nat Rev Immunol. 2017;17:97\u2013111.","journal-title":"Nat Rev Immunol"},{"key":"4017_CR46","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1038\/s41577-019-0215-7","volume":"20","author":"T Gong","year":"2020","unstructured":"Gong T, Liu L, Jiang W, Zhou R. DAMP-sensing receptors in sterile inflammation and inflammatory diseases. Nat Rev Immunol. 2020;20:95\u2013112.","journal-title":"Nat Rev Immunol"},{"key":"4017_CR47","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1038\/nm1523","volume":"13","author":"M Obeid","year":"2007","unstructured":"Obeid M, Tesniere A, Ghiringhelli F, Fimia GM, Apetoh L, Perfettini JL, Castedo M, Mignot G, Panaretakis T, Casares N, et al. Calreticulin exposure dictates the immunogenicity of cancer cell death. Nat Med. 2007;13:54\u201361.","journal-title":"Nat Med"},{"key":"4017_CR48","doi-asserted-by":"publisher","first-page":"e1431089","DOI":"10.1080\/2162402X.2018.1431089","volume":"7","author":"L Bezu","year":"2018","unstructured":"Bezu L, Sauvat A, Humeau J, Leduc M, Kepp O, Kroemer G. eIF2\u03b1 phosphorylation: a hallmark of immunogenic cell death. Oncoimmunology. 2018;7:e1431089.","journal-title":"Oncoimmunology"},{"key":"4017_CR49","doi-asserted-by":"publisher","first-page":"e108130","DOI":"10.15252\/embj.2021108130","volume":"40","author":"O Kepp","year":"2021","unstructured":"Kepp O, Bezu L, Yamazaki T, Di Virgilio F, Smyth MJ, Kroemer G, Galluzzi L. ATP and cancer immunosurveillance. Embo j. 2021;40:e108130.","journal-title":"Embo j"},{"key":"4017_CR50","doi-asserted-by":"publisher","first-page":"2068109","DOI":"10.1080\/2162402X.2022.2068109","volume":"11","author":"G Kofla","year":"2022","unstructured":"Kofla G, Radecke C, Frentsch M, Walther W, Stintzing S, Riess H, Bullinger L, Na IK. Conventional amphotericin B elicits markers of immunogenic cell death on leukemic blasts, mediates immunostimulatory effects on phagocytic cells, and synergizes with PD-L1 blockade. Oncoimmunology. 2022;11:2068109.","journal-title":"Oncoimmunology"},{"key":"4017_CR51","doi-asserted-by":"publisher","first-page":"1050","DOI":"10.1038\/nm1622","volume":"13","author":"L Apetoh","year":"2007","unstructured":"Apetoh L, Ghiringhelli F, Tesniere A, Obeid M, Ortiz C, Criollo A, Mignot G, Maiuri MC, Ullrich E, Saulnier P, et al. Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. Nat Med. 2007;13:1050\u20139.","journal-title":"Nat Med"},{"key":"4017_CR52","doi-asserted-by":"publisher","first-page":"972","DOI":"10.1126\/science.aad0779","volume":"350","author":"E Vacchelli","year":"2015","unstructured":"Vacchelli E, Ma Y, Baracco EE, Sistigu A, Enot DP, Pietrocola F, Yang H, Adjemian S, Chaba K, Semeraro M, et al. Chemotherapy-induced antitumor immunity requires formyl peptide receptor 1. Science. 2015;350:972\u20138.","journal-title":"Science"},{"key":"4017_CR53","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1038\/nm.3708","volume":"20","author":"A Sistigu","year":"2014","unstructured":"Sistigu A, Yamazaki T, Vacchelli E, Chaba K, Enot DP, Adam J, Vitale I, Goubar A, Baracco EE, Rem\u00e9dios C, et al. Cancer cell-autonomous contribution of type I interferon signaling to the efficacy of chemotherapy. Nat Med. 2014;20:1301\u20139.","journal-title":"Nat Med"},{"key":"4017_CR54","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1016\/bs.ircmb.2019.06.001","volume":"348","author":"J Sprooten","year":"2019","unstructured":"Sprooten J, Agostinis P, Garg AD. Type I interferons and dendritic cells in cancer immunotherapy. Int Rev Cell Mol Biol. 2019;348:217\u201362.","journal-title":"Int Rev Cell Mol Biol"},{"key":"4017_CR55","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1016\/j.cell.2017.01.017","volume":"168","author":"P Sharma","year":"2017","unstructured":"Sharma P, Hu-Lieskovan S, Wargo JA, Ribas A. Primary, adaptive, and Acquired Resistance to Cancer Immunotherapy. Cell. 2017;168:707\u201323.","journal-title":"Cell"},{"key":"4017_CR56","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1038\/s41568-019-0144-6","volume":"19","author":"C Saut\u00e8s-Fridman","year":"2019","unstructured":"Saut\u00e8s-Fridman C, Petitprez F, Calderaro J, Fridman WH. Tertiary lymphoid structures in the era of cancer immunotherapy. Nat Rev Cancer. 2019;19:307\u201325.","journal-title":"Nat Rev Cancer"},{"key":"4017_CR57","doi-asserted-by":"publisher","first-page":"1596652","DOI":"10.1080\/2162402X.2019.1596652","volume":"8","author":"P Liu","year":"2019","unstructured":"Liu P, Zhao L, Kepp O, Kroemer G. Crizotinib - a tyrosine kinase inhibitor that stimulates immunogenic cell death. Oncoimmunology. 2019;8:1596652.","journal-title":"Oncoimmunology"},{"key":"4017_CR58","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1038\/nrclinonc.2017.101","volume":"14","author":"WH Fridman","year":"2017","unstructured":"Fridman WH, Zitvogel L, Saut\u00e8s-Fridman C, Kroemer G. The immune contexture in cancer prognosis and treatment. Nat Rev Clin Oncol. 2017;14:717\u201334.","journal-title":"Nat Rev Clin Oncol"},{"key":"4017_CR59","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1126\/science.aaa4971","volume":"348","author":"TN Schumacher","year":"2015","unstructured":"Schumacher TN, Schreiber RD. Neoantigens in cancer immunotherapy. Science. 2015;348:69\u201374.","journal-title":"Science"},{"key":"4017_CR60","doi-asserted-by":"publisher","first-page":"eaat7807","DOI":"10.1126\/scitranslmed.aat7807","volume":"10","author":"L Galluzzi","year":"2018","unstructured":"Galluzzi L, Chan TA, Kroemer G, Wolchok JD, L\u00f3pez-Soto A. The hallmarks of successful anticancer immunotherapy. Sci Transl Med. 2018;10:eaat7807.","journal-title":"Sci Transl Med"},{"key":"4017_CR61","doi-asserted-by":"publisher","first-page":"e1655964","DOI":"10.1080\/2162402X.2019.1655964","volume":"8","author":"ME Rodriguez-Ruiz","year":"2019","unstructured":"Rodriguez-Ruiz ME, Buqu\u00e9 A, Hensler M, Chen J, Bloy N, Petroni G, Sato A, Yamazaki T, Fucikova J, Galluzzi L. Apoptotic caspases inhibit abscopal responses to radiation and identify a new prognostic biomarker for breast cancer patients. Oncoimmunology. 2019;8:e1655964.","journal-title":"Oncoimmunology"},{"key":"4017_CR62","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41435-021-00161-5","volume":"23","author":"B Decraene","year":"2022","unstructured":"Decraene B, Yang Y, De Smet F, Garg AD, Agostinis P, De Vleeschouwer S. Immunogenic cell death and its therapeutic or prognostic potential in high-grade glioma. Genes Immun. 2022;23:1\u201311.","journal-title":"Genes Immun"},{"key":"4017_CR63","doi-asserted-by":"publisher","first-page":"1721810","DOI":"10.1080\/2162402X.2020.1721810","volume":"9","author":"T Yamazaki","year":"2020","unstructured":"Yamazaki T, Buqu\u00e9 A, Ames TD, Galluzzi L. PT-112 induces immunogenic cell death and synergizes with immune checkpoint blockers in mouse tumor models. Oncoimmunology. 2020;9:1721810.","journal-title":"Oncoimmunology"},{"key":"4017_CR64","doi-asserted-by":"publisher","first-page":"2093518","DOI":"10.1080\/2162402X.2022.2093518","volume":"11","author":"P Liu","year":"2022","unstructured":"Liu P, Chen J, Zhao L, Hollebecque A, Kepp O, Zitvogel L, Kroemer G. PD-1 blockade synergizes with oxaliplatin-based, but not cisplatin-based, chemotherapy of gastric cancer. Oncoimmunology. 2022;11:2093518.","journal-title":"Oncoimmunology"},{"key":"4017_CR65","doi-asserted-by":"publisher","first-page":"1973197","DOI":"10.1080\/2162402X.2021.1973197","volume":"10","author":"A Petrazzuolo","year":"2021","unstructured":"Petrazzuolo A, Perez-Lanzon M, Liu P, Maiuri MC, Kroemer G. Crizotinib and ceritinib trigger immunogenic cell death via on-target effects. Oncoimmunology. 2021;10:1973197.","journal-title":"Oncoimmunology"},{"key":"4017_CR66","doi-asserted-by":"publisher","first-page":"1160","DOI":"10.1038\/s41590-020-0751-0","volume":"21","author":"T Yamazaki","year":"2020","unstructured":"Yamazaki T, Kirchmair A, Sato A, Buqu\u00e9 A, Rybstein M, Petroni G, Bloy N, Finotello F, Stafford L, Navarro Manzano E, et al. Mitochondrial DNA drives abscopal responses to radiation that are inhibited by autophagy. Nat Immunol. 2020;21:1160\u201371.","journal-title":"Nat Immunol"},{"key":"4017_CR67","doi-asserted-by":"publisher","first-page":"2057892","DOI":"10.1080\/2162402X.2022.2057892","volume":"11","author":"H Zhou","year":"2022","unstructured":"Zhou H, Tu C, Yang P, Li J, Kepp O, Li H, Zhang L, Zhang L, Zhao Y, Zhang T, et al. Carbon ion radiotherapy triggers immunogenic cell death and sensitizes melanoma to anti-PD-1 therapy in mice. Oncoimmunology. 2022;11:2057892.","journal-title":"Oncoimmunology"},{"key":"4017_CR68","doi-asserted-by":"publisher","first-page":"e98354","DOI":"10.15252\/embj.201798354","volume":"37","author":"LC Gomes-da-Silva","year":"2018","unstructured":"Gomes-da-Silva LC, Zhao L, Bezu L, Zhou H, Sauvat A, Liu P, Durand S, Leduc M, Souquere S, Loos F, et al. Photodynamic therapy with redaporfin targets the endoplasmic reticulum and Golgi apparatus. Embo J. 2018;37:e98354.","journal-title":"Embo J"},{"key":"4017_CR69","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1084\/jem.20100269","volume":"208","author":"Y Ma","year":"2011","unstructured":"Ma Y, Aymeric L, Locher C, Mattarollo SR, Delahaye NF, Pereira P, Boucontet L, Apetoh L, Ghiringhelli F, Casares N, et al. Contribution of IL-17-producing gamma delta T cells to the efficacy of anticancer chemotherapy. J Exp Med. 2011;208:491\u2013503.","journal-title":"J Exp Med"},{"key":"4017_CR70","doi-asserted-by":"publisher","first-page":"e1625687","DOI":"10.1080\/2162402X.2019.1625687","volume":"8","author":"AC Bloom","year":"2019","unstructured":"Bloom AC, Bender LH, Tiwary S, Pasquet L, Clark K, Jiang T, Xia Z, Morales-Kastresana A, Jones JC, Walters I, et al. Intratumorally delivered formulation, INT230-6, containing potent anticancer agents induces protective T cell immunity and memory. Oncoimmunology. 2019;8:e1625687.","journal-title":"Oncoimmunology"},{"key":"4017_CR71","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1016\/j.immuni.2015.11.024","volume":"44","author":"C Pfirschke","year":"2016","unstructured":"Pfirschke C, Engblom C, Rickelt S, Cortez-Retamozo V, Garris C, Pucci F, Yamazaki T, Poirier-Colame V, Newton A, Redouane Y, et al. Immunogenic chemotherapy sensitizes tumors to checkpoint blockade therapy. Immunity. 2016;44:343\u201354.","journal-title":"Immunity"},{"key":"4017_CR72","doi-asserted-by":"publisher","first-page":"271ps271","DOI":"10.1126\/scitranslmed.3010473","volume":"7","author":"L Zitvogel","year":"2015","unstructured":"Zitvogel L, Galluzzi L, Viaud S, V\u00e9tizou M, Daill\u00e8re R, Merad M, Kroemer G. Cancer and the gut microbiota: an unexpected link. Sci Transl Med. 2015;7:271ps271.","journal-title":"Sci Transl Med"},{"key":"4017_CR73","doi-asserted-by":"publisher","first-page":"2139","DOI":"10.1038\/s41467-019-10138-8","volume":"10","author":"C Darini","year":"2019","unstructured":"Darini C, Ghaddar N, Chabot C, Assaker G, Sabri S, Wang S, Krishnamoorthy J, Buchanan M, Aguilar-Mahecha A, Abdulkarim B, et al. An integrated stress response via PKR suppresses HER2 + cancers and improves trastuzumab therapy. Nat Commun. 2019;10:2139.","journal-title":"Nat Commun"},{"key":"4017_CR74","doi-asserted-by":"publisher","first-page":"1746","DOI":"10.1158\/0008-5472.CAN-15-1142","volume":"76","author":"J Fucikova","year":"2016","unstructured":"Fucikova J, Becht E, Iribarren K, Goc J, Remark R, Damotte D, Alifano M, Devi P, Biton J, Germain C, et al. Calreticulin expression in human non-small cell lung cancers correlates with increased Accumulation of Antitumor Immune cells and favorable prognosis. Cancer Res. 2016;76:1746\u201356.","journal-title":"Cancer Res"},{"key":"4017_CR75","doi-asserted-by":"publisher","first-page":"e1386829","DOI":"10.1080\/2162402X.2017.1386829","volume":"6","author":"AD Garg","year":"2017","unstructured":"Garg AD, More S, Rufo N, Mece O, Sassano ML, Agostinis P, Zitvogel L, Kroemer G, Galluzzi L. Trial watch: immunogenic cell death induction by anticancer chemotherapeutics. Oncoimmunology. 2017;6:e1386829.","journal-title":"Oncoimmunology"},{"key":"4017_CR76","doi-asserted-by":"publisher","first-page":"3088","DOI":"10.3390\/cells10113088","volume":"10","author":"M Matias","year":"2021","unstructured":"Matias M, Pinho JO, Penetra MJ, Campos G, Reis CP, Gaspar MM. The challenging melanoma landscape: from early drug discovery to clinical approval. Cells. 2021;10:3088.","journal-title":"Cells"},{"key":"4017_CR77","doi-asserted-by":"publisher","first-page":"1941","DOI":"10.1158\/1535-7163.MCT-21-0035","volume":"20","author":"R Montes de Oca","year":"2021","unstructured":"Montes de Oca R, Alavi AS, Vitali N, Bhattacharya S, Blackwell C, Patel K, Seestaller-Wehr L, Kaczynski H, Shi H, Dobrzynski E, et al. Belantamab Mafodotin (GSK2857916) drives immunogenic cell death and Immune-mediated antitumor responses in vivo. Mol Cancer Ther. 2021;20:1941\u201355.","journal-title":"Mol Cancer Ther"},{"key":"4017_CR78","doi-asserted-by":"publisher","first-page":"e1656502","DOI":"10.1080\/2162402X.2019.1656502","volume":"8","author":"W Xie","year":"2019","unstructured":"Xie W, Forveille S, Iribarren K, Sauvat A, Senovilla L, Wang Y, Humeau J, Perez-Lanzon M, Zhou H, Martinez-Leal JF, et al. Lurbinectedin synergizes with immune checkpoint blockade to generate anticancer immunity. Oncoimmunology. 2019;8:e1656502.","journal-title":"Oncoimmunology"},{"key":"4017_CR79","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1186\/s40425-018-0464-1","volume":"7","author":"L D\u2019Amico","year":"2019","unstructured":"D\u2019Amico L, Menzel U, Prummer M, M\u00fcller P, Buchi M, Kashyap A, Haessler U, Yermanos A, G\u00e9bleux R, Briendl M, et al. A novel anti-HER2 anthracycline-based antibody-drug conjugate induces adaptive anti-tumor immunity and potentiates PD-1 blockade in breast cancer. J Immunother Cancer. 2019;7:16.","journal-title":"J Immunother Cancer"},{"key":"4017_CR80","doi-asserted-by":"publisher","first-page":"e1637188","DOI":"10.1080\/2162402X.2019.1637188","volume":"8","author":"O Kepp","year":"2019","unstructured":"Kepp O, Zitvogel L, Kroemer G. Clinical evidence that immunogenic cell death sensitizes to PD-1\/PD-L1 blockade. Oncoimmunology. 2019;8:e1637188.","journal-title":"Oncoimmunology"},{"key":"4017_CR81","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.1186\/s12885-022-10225-y","volume":"22","author":"K Sharmni Vishnu","year":"2022","unstructured":"Sharmni Vishnu K, Win TT, Aye SN, Basavaraj AK. Combined atezolizumab and nab-paclitaxel in the treatment of triple negative breast cancer: a meta-analysis on their efficacy and safety. BMC Cancer. 2022;22:1139.","journal-title":"BMC Cancer"},{"key":"4017_CR82","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1016\/j.annonc.2019.10.021","volume":"31","author":"AS Mansfield","year":"2020","unstructured":"Mansfield AS, Ka\u017carnowicz A, Karaseva N, S\u00e1nchez A, De Boer R, Andric Z, Reck M, Atagi S, Lee JS, Garassino M, et al. Safety and patient-reported outcomes of atezolizumab, carboplatin, and etoposide in extensive-stage small-cell lung cancer (IMpower133): a randomized phase I\/III trial. Ann Oncol. 2020;31:310\u20137.","journal-title":"Ann Oncol"},{"key":"4017_CR83","doi-asserted-by":"publisher","first-page":"2217","DOI":"10.1111\/1759-7714.14051","volume":"12","author":"S Saito","year":"2021","unstructured":"Saito S, Toyokawa G, Momosaki S, Kozuma Y, Shoji F, Yamazaki K, Takeo S. Dramatic response to pembrolizumab with chemotherapy followed by salvage surgery in a lung cancer patient. Thorac Cancer. 2021;12:2217\u201320.","journal-title":"Thorac Cancer"},{"key":"4017_CR84","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1038\/nrm.2016.149","volume":"18","author":"R Weinlich","year":"2017","unstructured":"Weinlich R, Oberst A, Beere HM, Green DR. Necroptosis in development, inflammation and disease. Nat Rev Mol Cell Biol. 2017;18:127\u201336.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"4017_CR85","doi-asserted-by":"publisher","first-page":"a041020","DOI":"10.1101\/cshperspect.a041020","volume":"14","author":"DR Green","year":"2022","unstructured":"Green DR. Caspase activation and inhibition. Cold Spring Harb Perspect Biol. 2022;14:a041020.","journal-title":"Cold Spring Harb Perspect Biol"},{"key":"4017_CR86","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1038\/s41580-020-0232-1","volume":"21","author":"E Boada-Romero","year":"2020","unstructured":"Boada-Romero E, Martinez J, Heckmann BL, Green DR. The clearance of dead cells by efferocytosis. Nat Rev Mol Cell Biol. 2020;21:398\u2013414.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"4017_CR87","doi-asserted-by":"publisher","first-page":"2104551","DOI":"10.1080\/2162402X.2022.2104551","volume":"11","author":"R Zhang","year":"2022","unstructured":"Zhang R, Neighbors JD, Schell TD, Hohl RJ. Schweinfurthin induces ICD without ER stress and caspase activation. Oncoimmunology. 2022;11:2104551.","journal-title":"Oncoimmunology"}],"container-title":["Journal of Translational Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-023-04017-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12967-023-04017-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-023-04017-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,2]],"date-time":"2023-03-02T06:10:41Z","timestamp":1677737441000},"score":1,"resource":{"primary":{"URL":"https:\/\/translational-medicine.biomedcentral.com\/articles\/10.1186\/s12967-023-04017-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,2]]},"references-count":87,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["4017"],"URL":"https:\/\/doi.org\/10.1186\/s12967-023-04017-6","relation":{},"ISSN":["1479-5876"],"issn-type":[{"value":"1479-5876","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,2]]},"assertion":[{"value":"24 January 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 February 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 March 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All authors provided their consent to publication.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"LG is\/has been holding research contracts with Lytix Biopharma, Promontory and Onxeo, has received consulting\/advisory honoraria from Boehringer Ingelheim, AstraZeneca, OmniSEQ, Onxeo, The Longevity Labs, Inzen, Imvax, Sotio, Promontory, Noxopharm, EduCom, and the Luke Heller TECPR2 Foundation, and holds Promontory stock options. OK is a scientific co-founder of Samsara Therapeutics. GK has been holding research contracts with Daiichi Sankyo, Eleor, Kaleido, Lytix Pharma, PharmaMar, Osasuna Therapeutics, Samsara Therapeutics, Sanofi, Sotio, Tollys, Vascage and Vasculox\/Tioma. GK has been consulting for Reithera. GK is on the Board of Directors of the Bristol Myers Squibb Foundation France. GK is a scientific co-founder of everImmune, Osasuna Therapeutics, Samsara Therapeutics and Therafast Bio. GK is the inventor of patents covering therapeutic targeting of aging, cancer, cystic fibrosis and metabolic disorders. Among these, patents were licensed to Bayer (WO2014020041-A1, WO2014020043-A1), Bristoll-Myers Squibb (WO2008057863-A1), Osasuna Therapeutics (WO2019057742A1), PharmaMar (WO2022049270A1 and WO2022048775-A1), Raptor Pharmaceuticals (EP2664326-A1), Samsara Therapeutics (GB202017553D0), and Therafast Bio (EP3684471A1). EH is an employee of Sonata Therapeutics. FMM is an employee of Kite Pharma, Inc. All other authors have no conflicts to disclose.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"162"}}